Merck KGaA (MRK) promoted a former Sanofi executive to run its pharmaceutical business as it seeks to overcome competition and drug development setbacks that have dragged down sales. Belen Garijo, 53, will become president and chief executive officer of Merck Serono as of Oct. 1, the Darmstadt, Germany-based maker of cancer drug Erbitux said today in a statement. She joined Merck Serono as chief operating officer in 2011 from Sanofi, where she led European operations and oversaw the integration of the Genzyme acquisition.
Help employers find you! Check out all the jobs and post your resume.
